Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial
Year: 2026
Type: article
Abstract: BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) is associated with a high symptom burden and impaired health-related quality of life (HRQoL). This prespecified analysis from the phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) for tarlatamab versus standard-of-care (SoC) chemotherapy following first-line platinum-based therapy. METHODS: DeLLphi-304 is a multicenter, open-label, randomized phase 3 study in adults with ES-SCLC. PROs were assessed using validated instruments, including the EORTC QLQ-C30, EORTC QLQ-LC13, FACT-G GP5, BPI-SF, and the EQ-5D-5L visual analogue scale. Change from baseline, response rates, and time to deterioration in these PROs were analyzed. RESULTS: PRO data from all 509 patients enrolled were evaluated. Compliance with QLQ-C30 and QLQ-LC13 assessments remained above 69% through 19 weeks. A higher proportion of patients receiving tarlatamab achieved symptom or functional improvement at 19 weeks compared with SoC in chest pain (19% vs 10%), cough (35% vs 26%), dyspnea (22% vs 7%), physical functioning (13% vs 8%), and global health status (23% vs 15%), respectively. Tarlatamab also delayed deterioration in symptoms, physical functioning, and pain at worst relative to SoC. FACT-G GP5 results indicated that patients receiving tarlatamab were less bothered by treatment side effects over time. CONCLUSIONS: In addition to its previously reported antitumor activity, tarlatamab demonstrated clinically meaningful improvements in symptoms and HRQoL compared with SoC. These findings support a favorable benefit-risk profile of tarlatamab in patients previously treated for ES-SCLC.
Source: Lung Cancer
Authors: Giannis Mountzios, Philip E. Lammers, Longhua Sun, Byoung Chul Cho, Umut Demirci, Surein Arulananda, Mahmut Gumus, Salman Punekar, Antonio Lugini, Bo Zhu, Yan Yu, Tudor-Eliade Ciuleanu, Myung-Ju Ahn, Julien Mazieres, Martin Schuler, Fiona Blackhall, Tatsuya Yoshida, Franziska Dirnberger, Jessie Wang, Shuang Huang, Diana Gauto, Charles M. Rudin
Institutions: Henry Dunant Hospital, First Affiliated Hospital of Nanchang University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Memorial Ankara Hospital, Monash Health, Istanbul Medeniyet University, NYU Langone Health, New York University, Azienda Ospedaliera San Giovanni Addolorata, Army Medical University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Institute of Oncology Prof. Dr. Ion Chiricuta, Samsung Medical Center, Sungkyunkwan University, Université Toulouse III - Paul Sabatier, Hôpital Larrey, Essen University Hospital, University of Manchester, The Christie NHS Foundation Trust, National Cancer Centre Japan, National Cancer Center Hospital, Amgen (Germany), Amgen (United States), Memorial Sloan Kettering Cancer Center
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,390
Funder: Amgen
OpenAlex ID: W7202387600